United Kingdom (UK)
Recombinant monoclonal antibody to Apical complex glycoprotein CSL. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 3E2.
Alternative Name(s) of Target: CSL; αCSL; Apical complex glycoprotein, CSL (circumsporozoite-like) antigen
Immunogen: The original antibody was generated by immunizing mice with GP25-200 of Cryptosporidium parvum.
Specificity: This antibody binds the apical complex glycoprotein CSL of Cryptosporidium parvum. The apicomplexan protozoan Cryptosporidium parvum is a coccidian parasite that infects intestinal epithelium and causes diarrheal disease in humans and other agriculturally important food animals for which specific therapy and immunoprophylaxis are unavailable. Cryptosporidiosis is self-limiting in hosts with normal immune systems; however, in neonates, the elderly, and hosts having congenital or acquired immunodeficiency diseases or chemotherapy-induced immunosuppression, cryptosporidial enterocolitis may become chronic and have severe consequences.
Application Notes: Apical complex glycoprotein antigen of Cryptosporidium parvum is critical to infectivity and targets protective immunity. This antibody exhibited morphologic changes in sporozoites and merozoites characterized by rapid and progressive formation, posterior movement, and release of membranous Ag-mAb precipitates. This antibody was capable of recognizing 46-770 kDa sporozoite antigens and 1300 kDa antigen soluble glycoprotein exoantigen (CSL) expressed by merozoites in a western blot (PMID: 9029117). This antibody elicited circumsporozoite precipitate (CSP)-like reaction which is characterized by the progressive posterior formation and release of membranous antigen-MAb complexes, after which zoites are rendered noninfective. This antibody is capable of neutralizing C. parvum in vitro and also capable of passively protecting against oocyst challenge and infection in vivo. The identification of sporozoite-neutralizing antibody was done using ELISA (PMID: 10768951). This antibody was reported to be highly effective in in reducing, but not eliminating, persistent C. parvum infection (PMID: 11796330). This antibody in combination with PLA2 or LL37 was also used in the generation of a biocide fusion proteins to kill C. parvum sporozoites in vitro and in vivo (PMID: 20086143).
Antibody first published in:
Riggs et al. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J Immunol. 1997 Feb 15;158(4):1787-95. PMID:9029117
Note on publication:
Describes the generation of neutralizing antibodies against C. parvum and their role in providing passive immunization against cryptosporidiosis.